Therapeutic Innovation & Regulatory Science

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

Retrieved on: 
Wednesday, September 6, 2023

Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies.
  • Veracyte will combine these assets with its multi-omics testing and machine learning capabilities to create a Veracyte Biopharma Atlas reference database of genomic and immunomic biomarkers.
  • “This partnership will enable us to augment our Veracyte Biopharma Atlas reference database with a large number of patients tumor samples and data from innovative cancer therapies.
  • Ultimately, we believe this tool may help our biopharmaceutical partners accelerate development of new, precision-medicine therapies that improve outcomes for patients with cancer.”

Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research

Retrieved on: 
Tuesday, July 18, 2023

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons , the innovation engine at the core of one of the world’s largest private funders of cancer research, Cancer Research UK (CRUK), today announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons , the innovation engine at the core of one of the world’s largest private funders of cancer research, Cancer Research UK (CRUK), today announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230718140133/en/
    “Teaming up with Cancer Research Horizons to support exploratory drug discovery efforts, validating and de-risking biological targets has the potential to be groundbreaking for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.

ixlayer Announces Formation of Advisory Board

Retrieved on: 
Tuesday, November 1, 2022

ixlayer , the leading platform for health testing, announces today the formation of the ixlayer Health Testing Advisory Board .

Key Points: 
  • ixlayer , the leading platform for health testing, announces today the formation of the ixlayer Health Testing Advisory Board .
  • The ixlayer Health Testing Advisory Board will consist of industry leaders and experts who will serve as thought partners and strategists to further the movement of making health testing more accessible and affordable.
  • View the full release here: https://www.businesswire.com/news/home/20221101005418/en/
    ixlayer is appointing five members to its recently established ixlayer Heath Testing Advisory Board (iHTAB).
  • ixlayer is excited to take these next bold steps on our journey and welcomes these talented and respected professionals to our new advisory board, said Pouria Sanae , ixlayers Chief Executive Officer and co-founder.

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

Retrieved on: 
Wednesday, September 28, 2022

PETACH TIKVA, Israel, Sept. 28, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received confirmation from the European Medicines Agency (EMA) that D-PLEX100 is eligible for submission of a Marketing Authorization Application (MAA) in the European Union (EU) under the Agency’s centralized procedure.

Key Points: 
  • The centralized process eligibility is granted to D-PLEX100 under the Therapeutic Innovation criteria which underscores that D-PLEX100 provides a new alternative to patients in preventing post abdominal surgical site infections (SSIs).
  • This decision by the EMA allows us to potentially pursue registration of D-PLEX100 through the more efficient centralized review process.
  • D-PLEX100 received Breakthrough Therapy Designation from the U.S. FDA for the prevention of SSIs in patients undergoing elective colorectal surgery.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal surgical site infections.

Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting use of JOTROL™

Retrieved on: 
Tuesday, June 14, 2022

JUPITER, Fla. and BOSTON, June 14, 2022 /PRNewswire/ -- Jupiter Neurosciences, Inc. ("Jupiter" or the "Company"), today announced the publication in the Journal of Alzheimer's Disease of "JOTROL™, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model."  This research, performed in collaboration with the University of Miami Miller School of Medicine demonstrated that a novel, oral formulation of resveratrol, JOTROL™, was able to deliver therapeutically viable levels of resveratrol in a disease mouse model of Alzheimer's disease (AD).  The results showed that JOTROL™ significantly increased bioavailability over non-formulated resveratrol and that treatment resulted in AD-related gene expression changes, as well as changes in inflammatory gene and cytokine levels.  JOTROL™ may be effective as a prophylaxis and/or treatment for AD through increased expression and/or activation of neuroprotective genes, suppression of pro-inflammatory genes, and regulation of central and peripheral cytokine levels.  "This study demonstrated the much-improved bioavailability and activity of JOTROL™ over unformulated resveratrol in an animal model of Alzheimer's disease with extended drug exposure, stated lead author Professor Claes Wahlestedt, Associate Dean for Therapeutic Innovation, Department of Psychiatry & Behavioral Health at the University of Miami Miller School of Medicine."

Key Points: 
  • JUPITER, Fla. and BOSTON, June 14, 2022 /PRNewswire/ -- Jupiter Neurosciences, Inc. ("Jupiter" or the "Company"), today announced the publication in the Journal of Alzheimer's Disease of "JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model."
  • JOTROL, the Company's unique and patented platform product, is an enhanced resveratrol formulation designed to safely deliver therapeutically relevant levels of resveratrol.
  • In a Phase I first-in-man trial, JOTROL was administered in ascending doses to assess safety, tolerability, and pharmacokinetics.
  • The study was financed by a grant from the National Institute on Aging (NIA), entitled Safety and Pharmacokinetics of JOTROL for Alzheimer's Disease.

NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

Retrieved on: 
Tuesday, May 10, 2022

I am honored to join the board of NexImmune at this pivotal juncture in the Companys work, stated Dr. Gandhi.

Key Points: 
  • I am honored to join the board of NexImmune at this pivotal juncture in the Companys work, stated Dr. Gandhi.
  • Leena is an excellent addition the NexImmune Board.
  • She brings substantial translational and early clinical and immuno-oncology experience to our organization, said Sol J. Barer, Chairman of NexImmunes Board of Directors.
  • On behalf of the Company and the entire Board, I would like to welcome Leena to the team.

Mustafa Noor, MD, FACP, Joins Olatec as Chief Medical Officer

Retrieved on: 
Tuesday, March 15, 2022

Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Mustafa Noor, MD, FACP, joins the Company as Chief Medical Officer (CMO), following the decision of current CMO, Dr. Curt Scribner, to retire from the position.

Key Points: 
  • Olatec Therapeutics LLC, a leader in the developing class of selective NLRP3 inhibitors, today announced that Mustafa Noor, MD, FACP, joins the Company as Chief Medical Officer (CMO), following the decision of current CMO, Dr. Curt Scribner, to retire from the position.
  • View the full release here: https://www.businesswire.com/news/home/20220315005610/en/
    Mustafa Noor, MD, FACP joins Olatec Therapeutics as Chief Medical Officer (Photo: Business Wire)
    Dr. Noor remarked: I believe this is a great time to be joining the Olatec team.
  • Dr. Charles Dinarello, Olatecs Chief Scientific Officer, commented: we are so pleased to welcome Dr. Noor to our team.
  • From 2001 to 2006, as medical director at Bristol-Myers Squibb, Dr. Noor held positions of increasing responsibility in metabolic, cardiovascular, and antiviral programs.

Biotechnology and Life Sciences Innovators Recognized in the Inaugural BioTech Breakthrough Awards Program

Retrieved on: 
Wednesday, October 27, 2021

LOS ANGELES, Oct. 27, 2021 /PRNewswire-PRWeb/ -- BioTech Breakthrough , a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced the winners of the 2021 BioTech Breakthrough Awards program.

Key Points: 
  • LOS ANGELES, Oct. 27, 2021 /PRNewswire-PRWeb/ -- BioTech Breakthrough , a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced the winners of the 2021 BioTech Breakthrough Awards program.
  • The winning BioTech Breakthrough selections showcase technologies and companies that push ingenuity and exemplify the best in biotechnology solutions across the globe.
  • The mission of the annual BioTech Breakthrough Awards program is to conduct the industry's most comprehensive analysis and evaluation of the top technology companies, solutions and products in the life sciences and biotechnology industry today.
  • The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Food Science and BioAgriculture, and more.